Thermo Fisher ScientificWBO:TMOF +1.39%82 Cyclically Adjusted Price-to-FCF is 28.75 as of Jun. 24, 2026, which is 32% below its 10-year median of 42.06. GuruFocus rates WBO:TMOF with a GF Score™ of 82/100 and a GF Value™ of €507.47. The stock has 5 warning signs investors should review. Among 69 Medical Diagnostics & Research companies, Thermo Fisher Scientific ranks better than 50.72% on this metric.
The historical rank and industry rank for Thermo Fisher Scientific's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
WBO:TMOF'
s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 25.8 Med: 42.06 Max: 69.7
Current: 28.23
During the past years, Thermo Fisher Scientific's highest Cyclically Adjusted Price-to-FCF was 69.70. The lowest was 25.80. And the median was 42.06.
WBO:TMOF's Cyclically Adjusted Price-to-FCF is ranked better than 50.72% of 69
companies
in the Medical Diagnostics & Research industry
Industry Median: 30.27
vs WBO:TMOF: 28.23
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Thermo Fisher Scientific's adjusted free cash flow per share data for the three months ended in Mar. 2026 was €1.892. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €14.21 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thermo Fisher Scientific Cyclically Adjusted Price-to-FCF Related Terms
Thermo Fisher Scientific Cyclically Adjusted Price-to-FCF Historical Data
* Premium members only.
The historical data trend for Thermo Fisher Scientific's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:TMOF vs DHR, IDXX, A: Cyclically Adjusted Price-to-FCF Comparison
For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thermo Fisher Scientific Cyclically Adjusted Price-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Thermo Fisher Scientific's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted Price-to-FCF of 28.75 mean?
Thermo Fisher Scientific (WBO:TMOF) has a Cyclically Adjusted Price-to-FCF of 28.75 as of Jun. 24, 2026. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on Thermo Fisher Scientific and its competitors. This is 32% below median its historical median of 42.06. Over the past decade, Thermo Fisher Scientific's Cyclically Adjusted Price-to-FCF has ranged from 25.80 to 69.70. According to the industry distribution chart, Thermo Fisher Scientific ranks #34 out of 69 companies in the Medical Diagnostics & Research industry, placing it in the top 49.3%.
Is Thermo Fisher Scientific's Cyclically Adjusted Price-to-FCF too high?
Thermo Fisher Scientific's current Cyclically Adjusted Price-to-FCF of 28.75 is 32% below median its 10-year median of 42.06. Over the past 10 years, this metric has ranged from a low of 25.80 to a high of 69.70. The Medical Diagnostics & Research industry median Cyclically Adjusted Price-to-FCF is 30.27. Thermo Fisher Scientific's value of 28.75 is 5% below this industry median. Based on the distribution chart, Thermo Fisher Scientific ranks #34 out of 69 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Thermo Fisher Scientific has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Cyclically Adjusted Price-to-FCF compare to DHR and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Thermo Fisher Scientific ranks #34 out of 69 companies for Cyclically Adjusted Price-to-FCF. This puts Thermo Fisher Scientific in the upper half of its industry. The industry median Cyclically Adjusted Price-to-FCF is 30.27. Thermo Fisher Scientific's value of 28.75 is 5% below this benchmark. Historically, Thermo Fisher Scientific's own Cyclically Adjusted Price-to-FCF has ranged from 25.80 to 69.70 over the past decade. While the company's 10-year median is 42.06 vs. the industry median of 30.27, Thermo Fisher Scientific has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Price-to-FCF for a Medical Diagnostics & Research company?
The median Cyclically Adjusted Price-to-FCF among Medical Diagnostics & Research companies is 30.27, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted Price-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted Price-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thermo Fisher Scientific's current Cyclically Adjusted Price-to-FCF of 28.75 is 5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Price-to-FCF mean?
A high Cyclically Adjusted Price-to-FCF can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on Thermo Fisher Scientific and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted Price-to-FCF is 30.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current Cyclically Adjusted Price-to-FCF is 28.75, which is 32% below median its own 10-year median of 42.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Thermo Fisher Scientific (WBO:TMOF) has a current Cyclically Adjusted Price-to-FCF of 28.75. The stock's GF Value™ is €507.47, compared to a current price of €408.60 — trading 19.5% below its estimated fair value. The current Cyclically Adjusted Price-to-FCF is 28.75, which is 32% below median its 10-year median of 42.06 and 5% below the Medical Diagnostics & Research industry median of 30.27. Thermo Fisher Scientific's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Price-to-FCF calculated?
Cyclically Adjusted Price-to-FCF is calculated from a company's financial statements. For Thermo Fisher Scientific (WBO:TMOF), the current Cyclically Adjusted Price-to-FCF is 28.75 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (WBO:TMOF) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued.
The current stock price of €408.60 is trading 19.5% below its estimated GF Value™ of €507.47.
Key valuation signals for WBO:TMOF:
Cyclically Adjusted Price-to-FCF: 28.75 (32% below median its 10-year median of 42.06)
GF Value™: €507.47 vs. price of €408.60 (19.5% below fair value)
Industry Position: 5% below the Medical Diagnostics & Research median (#34 of 69)
No single metric tells the full story. See the WBO:TMOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
82GF Score
Get the complete analysis for WBO:TMOF
Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:TMOF has been successfully added to your 
